logo dark logo light logo
  • Home
  • About Us
    • About Us
    • Board Of Directors
    • Management
    • Scientific Advisors
    • Corporate Governance
  • Technology
    • Technology
    • Cymerus Platform Technology
    • Development Pathway
    • Potential Clinical Utility of MSCs
    • Intellectual Property
  • News
  • Investors
    • ASX Announcements
    • Activity Report / Financial Information
    • Presentations
    • Stock Information
  • FAQ
  • Contact Us
logo dark logo light logo
  • Home
  • About Us
    • About Us
    • Board Of Directors
    • Management
    • Scientific Advisors
    • Corporate Governance
  • Technology
    • Technology
    • Cymerus Platform Technology
    • Development Pathway
    • Potential Clinical Utility of MSCs
    • Intellectual Property
  • News
  • Investors
    • ASX Announcements
    • Activity Report / Financial Information
    • Presentations
    • Stock Information
  • FAQ
  • Contact Us
mobile-logo
  • Home
  • About Us
    • About Us
    • Board Of Directors
    • Management
    • Scientific Advisors
    • Corporate Governance
  • Technology
    • Technology
    • Cymerus Platform Technology
    • Development Pathway
    • Potential Clinical Utility of MSCs
    • Intellectual Property
  • News
  • Investors
    • ASX Announcements
    • Activity Report / Financial Information
    • Presentations
    • Stock Information
  • FAQ
  • Contact Us

Corporate Governance

Corporate Governance

  • Board Charter
  • Board Skills Matrix
  • Code of Conduct
  • Constitution
  • Continuous Disclosure Policy
  • Diversity Policy
  • Nomination Committee Charter
  • Performance Evaluation Policy
  • Procedures for Selection and Appointment of Directors
  • Remuneration Committee Charter
  • Remuneration Policy
  • Risk Management and Internal Compliance and Control Policy
  • Securities Trading Policy
  • Shareholder Communications Policy

About Us

  • About Us
  • Board Of Directors
  • Management
  • Scientific Advisors
  • Corporate Governance
logo

Level 3
62 Lygon Street
CARLTON, VIC 3053

Phone:
+61 (0) 412 119343

Latest News

  • FDA Grants CYP-001 Orphan Drug Designation; Reiterate Buy
  • Shaw and Partners Research Update: “1H18 Produced a De Risking and Increased Investor Interest“
  • H.C. Wainwright & Co. Research Update: “Cohort A Primary Evaluation Period Data Comes up Trumps; Reiterate Buy”
  • Shaw and Partners Research Flash Note: “Safety Study Provides Early Indication of Safety and Efficacy”
  • H.C. Wainwright & Co. Research Update: “Data Safety Monitoring Board Clears Trial to Enter Cohort B; Reiterate Buy”
  • Cynata To Drive Investor Support in Japan
© Cynata 2018
Website by Programmable Soda